Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.10 USD

87.10
5,944,229

+0.90 (1.04%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $87.11 +0.01 (0.01%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt

by Zacks Equity Research

Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.

Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels

by Zacks Equity Research

Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.

The Zacks Analyst Blog Highlights Amazon, Boston Scientific, Shopify and Cooper-Standard

by Zacks Equity Research

Amazon, Boston Scientific, Shopify and Cooper-Standard are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Amazon, Boston Scientific & Shopify

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Boston Scientific Corporation (BSX) and Shopify Inc. (SHOP), as well as a micro-cap stock, Cooper-Standard Holdings Inc. (CPS).

Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia

by Zacks Equity Research

Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.

Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?

by Zacks Equity Research

Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.

Here's Why Investors Should Hold Acadia (ACHC) Stock for Now

by Zacks Equity Research

Acadia Healthcare (ACHC) remains well-poised for growth on the back of the solid demand for behavioral healthcare services, continuous pursuit of expansion initiatives and a notable financial position.

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

by Zacks Equity Research

Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.

Should Quest Diagnostics (DGX) be in Your Portfolio Now?

by Zacks Equity Research

Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.

Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma

by Zacks Equity Research

Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.

AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall second-quarter performance.

Nalak Das headshot

Buy 5 Surging Old Economy Stocks to Tap Market Rally

by Nalak Das

Five old economy stocks with strong near-term potential are: NEM, GE, PFE, PGR, BSX.

Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Reasons to Hold Patterson Companies (PDCO) in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.

PacBio (PACB) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.

HAE or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. BSX: Which Stock Is the Better Value Option?

McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.

Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.

DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its second-quarter performance.

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Baxter (BAX) Q2 Earnings Beat Estimates, '24 EPS View Raised

by Zacks Equity Research

Baxter (BAX) reports better-than-expected second-quarter earnings and sales. Its quarterly results reflect solid demand for a range of its medically essential products.